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Praziquantel, an effective drug for the treatment of 
schistosomiasis, isa racemic compound containing equal 
parts of its optical isomers, laevo-praziquantel (L-Pra), 
and dextro-praziquantel (D-pra). L-Pra has been identi- 
tied as the active component against Schistosoma japoni- 
cum infections (ANDREWS, 1985; TANAKA et al., 1989), 
and has been demonstrated to have greater efficacy and 
safety than the racemic compound in field trials (WV et 
al., 1991). L-Pra has also been identified as the probable 
active compound against S. mansoni infection from 
studies in vitro (ANDRRWS, 1985; STAUDT et al., 
1992), and a study in vivo against adult male worms 
(XIAO & CAT-TO, 1989). The purpose of the present 
study was to extend previous work, by assessing whether 
L-Pra is also the active component of praziquantel when 
used against juvenile S. mansoni nfections, through a 
series of experiments in vivo on mice. Attention was given 
to the effects of each enantiomer on female worms, since 
these are the source of pathology and transmission. 
Praziquantel for each experiment was supplied by the 
Shanghai No. 6 Pharmaceutical Factory, China. L-Pra 
and D-Fra were synthesized by the Institute of Parasitic 
Diseases, Shanghai. In ethanol at ll”C, the optical 
rotation of L-Pra was -132.43, and that of D-Fra was 
+ 133.2 1. The optical specificity of the enantiomers was 
confirmed by high-performance liquid chromatography, 
which revealed that the L-Pra was pure, whereas the D- 
Pra was slightly contaminated (<2%) by L-Pra. 
In each experiment, groups of 2-5 female MORO 
mice (SPF) were inoculated with 60 cercariae of the 
Liberia strain of S. mansoni by subcutaneous injection in 
the root of the tail. Six weeks later the mice were treated 
intragastrically, sacrificed at a defined time point after 
medication, and the liver and intestines were removed 
and separated. The liver was placed in a 20 X 30-cm 
plastic folder and compressed between 2 glass plates until 
the parenchyma was a thin transparent layer. Worms 
were then easily counted and sexed at X10 magnifica- 
tion. The mesenteric veins were placed in a Petri dish and 
examined with a stereoscopic microscope. 
In preliminary experiments, we determined the rela- 
tionship between the dose of each enantiomer and the 
extent of hepatic shifting. Mice were treated with either 
L-Pra or D-Fra at a single dose of 2.5 mg/kg, 5.0 mg/kg 
or 10 mg/kg, sacrificed 1 h after treatment, and the 
numbers of worms in the mesenteric veins and livers 
were compared. Although the numbers of mice in each 
group were too small to allow statistical analysis, consid- 
erably more worms were found in the livers of mice 
treated with L-Pra than either control mice or mice given 
D-&a (Table 1). There were more than twice as many 
male worms recovered from mice than female worms, 
partly owing to an imbalance in the sex ratio of cercariae. 
We also observed an apparent disproportionate ffect of 
D-Fra on male worms, for unknown reasons. 
The results of these experiments indicated that hepatic 
shifting was largely attributable to the activity of L-Pra. In 
further experiments, we then tested the hypothesis that 
D-Fra would cause shifting at higher doses. In these 
experiments, L-Pra was given intragastrically to infected 
mice at a dose of 10 mg/kg, whereas D-Pi-a was given at 
higher doses of 50 mg/kg or 100 mg/kg. All schisto- 
somes in mice given L-Pra were shifted to the livers, 
whereas this occurred among only 25% and 80% of the 
worms in mice treated with 50 mg/kg or 100 mg/kg of D- 
Pra. In the control group, only 7.9% of the worms had 
shifted. The hepatic shift of the worms in the D-pra high- 
dose group was most likely due to the small amount of L- 
Pra contamination in the D-Fra compound, and/or a 
disproportionate ffect on male worms which formed the 
majority of the worm population. 
Finally, we investigated the comparative efficacy of 
racemic praziquantel (Pra) and each isomer in mice 
infected with S. mansoni for 7 weeks and sacrificed 4 
weeks after treatment (Table 2). ANOVA was used to 
test for differences in worm burdens after treatment. 
When infected mice were treated intragastrically with L- 
Pra 150 mg/kg or Pra 300 mg/kg, the mean worm 
burdens in these groups were significantly lower than in 
the control group (L-Pra vs control: F = 17.12, 
P = 0.0005; Pra vs control: F = 53.37, P<O.OOOl), 
and the mean worm burden was significantly lower in the 
Pra group than in the 50 mg/kg L-Pra group (F = 13.79, 
P = 0.0012). Increasingthe dose ofL-Pra to 300 mg/kg 
resulted in worm burden reductions that were signifi- 
Table 1. Effects of praziquantel enantiomers on numbers and distribution of S. mansoni in mice 
Drug and dose (mg/kg) n 
Control 5 
Male 
3.8 
Liver 
Female 
0 
Overall 
3.8 
Mesenteric veins 
Male Female Overall 
9.2 5.6 14.8 
L-Pra 
2.5 
5 
10 
5 8.8 11.2 3.0 
: 11.0 17.3 5.8 23.5 16.7 ;:; 1.0 0.5 1.0 ;:g 1.5 
D-Fra 
2.5 2 11.0 0 11.0 14.0 9.0 23.0 23.0 -- 
5 150 4 3 4 5.7 ;:; 0.3 .   6.0 .  4.7 7.3 .  7.0 5.5 6.3 12.8 
6.3 
3 312.8 
13.3 
Mean worm burdens of each sex (1 h after treatment) in the livers and mesenteric veins of mice were calculated for each treatment group.  li r   t ri  i  f i  r  l l t  f r  tr t t roup. 
1z, number of mice in each group. 
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Table 2. Efficacy of praziquantel enantiomers against 7-week infections 
with S. mansoni in mice 
Drug and dose 
(mdk) 
Control 
- 
Pra 
300 
L-Pra 
50 
150 
300 
D-Pra 
150 
300 
600 
n 
10 
9 
9 
10 
10 
10 
10 
10 
Mice without female Mean worm burden 
worms (* SD> 
0 41.2 f 11.6 
2 7.9 f 7.6 
0 21.7 & 8.5 
3 2.6 IL 1.3 
7 0.7 f 0.9 
0 37.2 f 9.4 
0 38.0 f 11.7 
0 36.8 zt 10.1 
The arithmetic mean worm burden was recorded for each group 4 weeks after treatment, 
together with the number of animals free of female worms. n, number of mice in each group. 
cantly greater than those gained with 50 mg/kg of L-Pra 
(F = 20.7, P = 0.0014), or 150mg/kg of L-R-a 
(F = 14.4, P = 0.001). Worm burdens were lower in 
the L-Pra group given 300 mg/kg than in the Pra group 
given 300 mg/kg, but the difference was not significant, 
presumably because of the low sample size (F = 2.8, 
P = 0.13 14). In further comparing these groups, we also 
observed that the L-R-a group had more mice without 
female worms than the Pra group. The lack of efficacy of 
D-Pra was clearly shown in this experiment-none of the 
3 doses given to different groups of mice reduced the 
worm burdens significantly when compared to the con- 
trol or any other treatment group. 
Our main conclusion tiom these experiments is that L- 
Pra is indeed the active enantiomer of praziquantel when 
the drug is used to treat juvenile S. mansoni infections. 
Pure L-Pra may also be more efficacious than the racemic 
mixture, but larger-scale studies are required to test this 
hypothesis further. There was no evidence of a dispro- 
portionate effect of L-ha on female worms in terms of 
hepatic shifting, which suggests that the relatively high 
number of mice without female worms in the L-Pra 
300 mg/kg group is due to an equally proportionate 
effect of the enantiomer on both worm sexes, and a high 
male-to-female sex ratio in the cercariae. Overall, these 
results lend weight to the idea that treatment with L-Pra 
may be equally efficacious at lower doses than are 
recommended for the racemic mixture. This could 
reduce the risk of side-effects in treated patients, pro- 
vided that side-effects are associated with D-Pra, or at 
least not disproportionately associated with L-Pra. 
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